Shares of Regeneron Pharmaceuticals Inc. slipped 3.63% to $527.78 Friday, on what proved to be an all-around poor trading ...

The primary endpoint of comprehensive disease control was defined as a combination of clinical remission (CDAI under 150; ...

We recently compiled a list of the 10 Jim Cramer Stocks with Huge Upside Potential. In this article, we are going to take a ...

The new plans are in addition to $21B that the drug manufacturer has already committed to U.S. research, development and ...

With President Donald Trump expected to deliver a drug pricing order on Monday that Big Pharma and patient groups alike have ...

Despite a risk for severe side effects, pembrolizumab has a record of improving recurrence-free survival that makes it an appealing treatment for advanced melanoma.

A decision by the First Circuit Court of Appeals has deepened the legal debate surrounding False Claims Act (FCA) actions ...

The Saudi national team for science and engineering departed for the United States on Friday to compete in the Regeneron International Science and Engineering Fair (ISEF 2025), which will be held in ...

The latest headlines from Newswires.